Debomita Sengupta,
Chittaranjan National Cancer Institute (CNCI), India
Title: Assessing the possibilities and risks associated with aurora kinase a targeting drug in breast cancer
Biography
Biography: Debomita Sengupta,
Abstract
Given the overexpression of Aurora Kinase A (AURKA) in 94% of breast cancer cases, AURKA-inhibitors have been tested without any betterment in response compared to conventional chemotherapeutic regimen proving that AURKA expression is dispensable during dissemination of breast cancer stem cells (BCSCs). In our study, we have observed AURKA upregulation by Oct4/Sox2 indicating that BCSCs may be targeted through AURKA in the cells undergoing active cell-cycle. However, the quiescent BCSCs without AURKA expression were found to circulate in patient blood irrespective of chemotherapeutic regimen demonstrating lack of the proliferative phase as an escaping route against chemotherapeutic regimen or AURKA-targeted therapies.